source
- ICER reports two-thirds of new drugs launched 2022-2025 priced well above cost-effectiveness thresholdsICER’s latest analysis of launch prices for new prescription medicines shows a sharp rise in net costs between 2022 and 2025. After adjusting for inflation, the median price climbed from $190,000 i…
- Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trialRapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…